Mayne Pharma Group Limited (ASX:MYX)
5.05
+0.20 (4.12%)
Nov 6, 2025, 4:18 PM AEST
Mayne Pharma Group Revenue
In the fiscal year ending June 30, 2025, Mayne Pharma Group had annual revenue of 408.10M AUD with 5.07% growth. Mayne Pharma Group had revenue of 195.04M in the half year ending June 30, 2025.
Revenue
408.10M
Revenue Growth
+5.07%
P/S Ratio
1.01
Revenue / Employee
831.15K
Employees
491
Market Cap
410.29M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 408.10M | 19.70M | 5.07% |
| Jun 30, 2024 | 388.40M | 204.81M | 111.56% |
| Jun 30, 2023 | 183.59M | 26.44M | 16.82% |
| Jun 30, 2022 | 157.15M | -243.63M | -60.79% |
| Jun 30, 2021 | 400.78M | -56.20M | -12.30% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CSL Limited | 23.73B |
| Ramsay Health Care | 17.79B |
| Sonic Healthcare | 9.65B |
| Ansell | 3.06B |
| Cochlear | 2.34B |
| Regis Healthcare | 1.16B |
| Telix Pharmaceuticals | 1.01B |
| Neuren Pharmaceuticals | 218.86M |
Mayne Pharma Group News
- 6 days ago - Chalmers all but kills Mayne Pharma takeover bid - The Australian Financial Review
- 6 days ago - Australia's Mayne Pharma falls as treasurer considers blocking Cosette's $437 million bid - Reuters
- 7 days ago - ASX 200 LIVE: Shares rise as gold miners rally; Origin slumps 5pc; Endeavour drops; Steadfast down 7pc Mayne Pharma tanks - The Australian Financial Review
- 22 days ago - Cosette's attempt to drop $438 million Mayne Pharma deal denied by court - Reuters
- 22 days ago - ASX200 LIVE: ASX resets record high; real estate stocks, gold miners rip - The Australian Financial Review
- 22 days ago - Court rules US giant can’t terminate Mayne Pharma takeover - The Australian Financial Review
- 6 weeks ago - Mayne Pharma director questioned management integrity, court hears - The Australian Financial Review
- 6 weeks ago - Inside Mayne Pharma suitor’s battle to sink Project Crocodile - The Australian Financial Review